Adial Pharmaceuticals regains Nasdaq compliance, plans Phase 3 clinical trial for AUD treatment.
ByAinvest
Tuesday, Feb 24, 2026 9:01 am ET1min read
ADIL--
Adial Pharmaceuticals has regained compliance with Nasdaq's listing requirement, having maintained a minimum bid price of $1.00 per share for 10 consecutive business days. The company has now resolved its Nasdaq compliance issue and is advancing its AD04 treatment for addiction and related disorders. AD04 has shown promising results in reducing heavy drinking and has the potential to treat other addictive disorders. Adial is planning a new Phase 3 clinical trial program and is engaged in strategic partnering discussions to support further development and commercialization.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet